ENvue Medical, Inc.
No enriched coverage for $FEED in the last 7 days.
No SEC Form 4 filings for $FEED in the last 30 days.
See all $FEED insider activity →ENvue Medical secured a $1M note from Alpha Capital, with $250K initially funded, to improve liquidity. The company also amended its Series X Preferred Stock terms, lowering the conversion price to $0.50 per share to support future financing, according to the company.
ENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Secured Promissory Note and Security Agreement On October 8, 2026, ENvue Medical, Inc. (the “Company”) entered into a Secured Promissory Note and Security Agreement (the “Note and Security Agreement”) with Alpha Capital Anstalt
Pro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.
Recent FEED coverage spans corporate actions, earnings and financial news.
ENvue Medical secured a $1M note from Alpha Capital, with $250K initially funded, to improve liquidity. The company also amended its Series X Preferred Stock terms, lowering the conversion price to $0.50 per share to support future financing, according to the company.
The new financing provides short‑term liquidity but adds debt at a 10% rate, potentially diluting equity if conversion occurs.
Visibility at a major conference could drive hospital sales and boost the stock.
The split reduced share count and lowered the price, pushing the stock toward its 52‑week low.
The reverse split reduces share count and may improve price perception, affecting liquidity and short‑term trading.
AlphAI scores every news story that mentions FEED with an AI model for sentiment and relevance, and aggregates insider trades from ENvue Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ENvue Medical secured a $1M note from Alpha Capital, with $250K initially funded, to improve liquidity. The company also amended its Series X Preferred Stock terms, lowering the conversion price to $0.50 per share to support future financing, according to the company.
1 min readENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Secured Promissory Note and Security Agreement On October 8, 2026, ENvue Medical, Inc. (the “Company”) entered into a Secured Promissory Note and Security Agreement (the “Note and Security Agreement”) with Alpha Capital Anstalt
1 min readPro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.
2 min readENvue Medical (FEED) stock fell 1.5% after a 1-for-12 reverse stock split took effect, reducing shares outstanding. The company's stock opened at $4.42 and dropped to $4.05. The split does not change ownership percentages but comes amid broader market declines due to inflation concerns and geopolitical tensions.
2 min readENvue Medical (FEED) announced a 1-for-12 reverse stock split, effective September 1, 2026. Outstanding shares will reduce from 11.08 million to 923,718. The split was approved by the board and does not affect shareholders' ownership or voting power. FEED is trading down 7.04% at $0.34.
1 min readENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 14, 2026, ENvue Medical, Inc. (the “ Company ”) held a special meeting of stockholders (the “ Special Meeting ”). The final voting results of the Special Meeting are set forth below. Stockholders voted on t
3 min readENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Committed Equity Facility of up to $50 million On August 12, 2026, ENvue Medical, Inc. (the “Company”) entered into a Common Shares Purchase Agreement (the “Purchase Agreement”), with an institutional investor (the “Investor”)
4 min readENvue Medical (NASDAQ: FEED) said Zeev Rotstein, M.D. was appointed Chairman of the Board, replacing David Johnson, who and Nino Pionati are departing. ENvue also added Zvi Joseph and Lior Buchman as directors. The company cited Joseph’s AI governance background at Amdocs and Buchman’s $320 million in executed financings and M&A.
3 min readENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001326706 0001326706 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readENvue Medical (NASDAQ: FEED) said it developed and demonstrated a first prototype of ENvue Drive, a robotic-assisted, AI-integrated tool within its electromagnetic navigation platform. The prototype combined Ask Oscar AI navigation with robotic tube advancement in a simulated bedside enteral procedure. ENvue Drive is investigational and not FDA-cleared.
3 min read
